(0.98%) 5 067.51 points
(0.94%) 38 258 points
(1.53%) 15 843 points
(0.15%) $79.12
(5.75%) $2.04
(0.21%) $2 315.90
(0.69%) $26.93
(1.12%) $965.60
(-0.10%) $0.932
(-0.41%) $10.98
(-0.12%) $0.798
(-1.40%) $91.96
Quarter results today
(bmo 2024-05-02)
Expected move: +/- 10.30%
@ $75.94
Išleistas: 2 geg. 2024 @ 16:30
Grąža: 0.80%
Ankstesnis signalas: geg. 1 - 22:37
Ankstesnis signalas:
Grąža: 11.73 %
Live Chart Being Loaded With Signals
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide...
Stats | |
---|---|
Šios dienos apimtis | 2.68M |
Vidutinė apimtis | 857 650 |
Rinkos kapitalizacija | 5.25B |
EPS | $0 ( 2024-02-22 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 16.46 |
ATR14 | $4.43 (5.78%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-17 | Niedzwiecki Daniel | Sell | 177 | Common Stock |
2024-04-17 | Blanchfield Paul | Sell | 455 | Common Stock |
2024-04-15 | Sabens Andrea | Sell | 341 | Common Stock |
2024-03-25 | Morgan Amanda Michelle | Sell | 0 | Common Stock |
2024-03-25 | Morgan Amanda Michelle | Sell | 10 310 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
16.10 |
Last 100 transactions |
Buy: 597 665 | Sell: 442 511 |
Tūris Koreliacija
Lantheus Holdings Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
PDFS | 0.964 |
LMNR | 0.964 |
RAM | 0.957 |
AMPH | 0.957 |
SGEN | 0.956 |
OMAB | 0.948 |
GEOS | 0.947 |
ALTR | 0.943 |
ANSS | 0.942 |
NSIT | 0.941 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
WTBA | -0.961 |
FGBI | -0.957 |
GNTY | -0.957 |
ALXO | -0.954 |
ALLK | -0.949 |
ACRX | -0.947 |
TNGX | -0.943 |
AROW | -0.941 |
MICS | -0.941 |
RDVT | -0.94 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Lantheus Holdings Inc Koreliacija - Valiuta/Žaliavos
Lantheus Holdings Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $1.30B |
Bruto pelnas: | $709.54M (54.73 %) |
EPS: | $4.79 |
FY | 2023 |
Pajamos: | $1.30B |
Bruto pelnas: | $709.54M (54.73 %) |
EPS: | $4.79 |
FY | 2022 |
Pajamos: | $935.06M |
Bruto pelnas: | $581.70M (62.21 %) |
EPS: | $0.410 |
FY | 2021 |
Pajamos: | $425.21M |
Bruto pelnas: | $187.70M (44.14 %) |
EPS: | $-1.054 |
Financial Reports:
No articles found.
Lantheus Holdings Inc
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.